Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 9/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | LATS1 | O95835 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885307 | 1.00 | PIM1 (0.47) | PIM1PIM3PIM2HTR2CASIC3 | |
| SCHEMBL4881237 | 1.00 | PIM1 (0.47) | PIM1PIM3PIM2HTR2CASIC3 | |
| SCHEMBL16933690 | 0.79 | ROCK1 (0.47) | HTR2CGSK3BLATS1USP30HTR2B | |
| SCHEMBL15578384 | 0.79 | ROCK1 (0.47) | HTR2CGSK3BLATS1USP30HTR2B | |
| SCHEMBL29384430 | 0.79 | ROCK1 (0.47) | HTR2CGSK3BLATS1USP30HTR2B | |
| SCHEMBL9213161 | 0.79 | HTR3E (0.56) | PIM1PIM3PIM2HTR2CGSK3B | |
| SCHEMBL29668691 | 0.79 | HTR3E (0.56) | PIM1PIM3PIM2HTR2CGSK3B | |
| SCHEMBL21098721 | 0.77 | ALOX5 (0.48) | PIM1PIM3PIM2HTR2CHTR2A | |
| SCHEMBL21098718 | 0.77 | ALOX5 (0.48) | PIM1PIM3PIM2HTR2CHTR2A | |
| SCHEMBL20141500 | 0.76 | PLD1 (0.54) | PIM1PIM3PIM2HTR2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1831188-A1 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065706-A9 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006065706-A9 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006065706-A1 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | HTR2C, HTR2A, HTR5A | PIM1 4871/4885PIM3 4788/4885PIM2 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.